EBITDA grew 29% to Rs 928 crore, while net profit for the period stood at Rs 85 crore, up 428% year-over-year as against a loss of Rs 16 crore in the same period last financial year, the company said in a notice to the stock exchanges.
“With the Board approval of the settlement of structured debt obligations, we will strengthen our balance sheet, enhance financial flexibility, and improve profitability,” said Kiran Mazumdar-Shaw, Chairperson, Biocon Group.
“Our partnership with the State of California through Civica Inc under the CalRx initiative, marks a landmark step in expanding affordable insulin access in the US, with potential to extend to other states,” she said. “With a resilient foundation, differentiated portfolio, and clear strategy, we are well positioned to sustain growth and deliver long-term value to our stakeholders,” Shaw added.
The company’s generics business continued its steady performance in Q2 with a growth of 24% driven primarily by an uptick in recently launched products in the US and EU, as well as growth in the generic formulations base business, and the API business.
“A key highlight of this quarter was the inauguration of Biocon’s first OSD manufacturing facility in the United States, a significant step towards expanding access to our vertically integrated portfolio for patients in the region. We commenced filings for Semaglutide (gOzempic) in various markets, including Canada and Brazil,” said Siddharth Mittal, CEO & Managing Director, Biocon Limited.Biocon Biologics posted 25% year-on-year revenue growth in Q2 and an over 40% increase in EBITDA. Sequentially, revenues grew 11%, driven by market share expansion in key therapy areas and successful new product launches. “In the US, we continue to expand access to biosimilars by leveraging the strength of our commercial platform. In FY26, we launched four biosimilars across key global markets and remain on track for the bDenosumab launch,” said Shreehas Tambe, CEO & Managing Director, Biocon Biologics.
